Psoriasis: Current perspectives with an emphasis on treatment

被引:63
作者
Linden, KG [1 ]
Weinstein, GD [1 ]
机构
[1] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92697 USA
关键词
D O I
10.1016/S0002-9343(99)00284-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An individualized treatment regimen is necessary for each patient with psoriasis because of the diverse nature of the disease. The manifestation of psoriasis, the severity and extent of the lesions, and the medical history and lifestyle of the patient are important factors that determine the selection of treatment, but in general therapies with the fewest side effects are preferred. First-line topical treatments are corticosteroids, calcipotriene, and tazarotene. If topical treatments are unsuccessful, phototherapy with ultraviolet B or photochemotherapy with psoralens plus ultraviolet A (PUVA) are the next choices. If psoriasis fails to respond to an adequate trial of topical therapy or phototherapy, systemic therapies including methotrexate, acitretin, or cyclosporin should be initialed. Because the regimens involved in systemic and phototherapy are complex and require frequent dose adjustments and specialized equipment, the patient should be referred to a dermatologist when topical therapy is not effective. Am J Med. 1999;107;595-605. (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:595 / 605
页数:11
相关论文
共 65 条
[1]   PHOTOTHERAPY [J].
ABEL, EA .
DERMATOLOGIC CLINICS, 1995, 13 (04) :841-&
[2]  
ADAMS PF, 1995, VITAL HLTH STAT, V10, P193
[3]   VITAMIN-D ANALOGS AND PSORIASIS [J].
BERTHJONES, J ;
HUTCHINSON, PE .
BRITISH JOURNAL OF DERMATOLOGY, 1992, 127 (02) :71-78
[4]   USE OF BUDESONIDE TURBUHALER(R) IN YOUNG-CHILDREN SUSPECTED OF ASTHMA [J].
BISGAARD, H ;
PEDERSEN, S ;
NIKANDER, K .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (04) :740-742
[5]  
Bodor N, 1993, Curr Probl Dermatol, V21, P11
[6]  
Boehm MF., 1995, EXPERT OPIN INV DRUG, V4, P593, DOI DOI 10.1517/13543784.4.7.593
[7]   COMPARATIVE-STUDY OF CALCIPOTRIENE (MC-903) OINTMENT AND FLUOCINONIDE OINTMENT IN THE TREATMENT OF PSORIASIS [J].
BRUCE, S ;
EPINETTE, WW ;
FUNICELLA, T ;
ISON, A ;
JONES, EL ;
LOSS, R ;
MCPHEE, ME ;
WHITMORE, C .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 31 (05) :755-759
[8]   T-CELL ACTIVATION IS POTENTIATED BY CYTOKINES RELEASED BY LESIONAL PSORIATIC, BUT NOT NORMAL, EPIDERMIS [J].
CHANG, EY ;
HAMMERBERG, C ;
FISHER, G ;
BAADSGAARD, O ;
ELLIS, CN ;
VOORHEES, JJ ;
COOPER, KD .
ARCHIVES OF DERMATOLOGY, 1992, 128 (11) :1479-1485
[9]  
CHU AC, 1995, BRIT J CLIN PRACT, V49, P131
[10]   Long-term effectiveness and safety of topical calcipotriene for psoriasis [J].
Cullen, SI ;
Drake, L ;
Kahn, T ;
Katz, HI ;
Loss, RW ;
Jarratt, MT ;
Funicella, T ;
Whitmore, C ;
Luber, H ;
Ison, A ;
Jones, EL ;
Primmer, S ;
Huerter, C ;
Kingsley, D ;
Moss, H ;
Bruce, S ;
Milbauer, J ;
Kantor, I ;
Lederman, J ;
Shavin, J .
SOUTHERN MEDICAL JOURNAL, 1996, 89 (11) :1053-1056